DCGO
DocGo Inc.
DCGO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
NVO
Novo Nordisk A/S
NVO has the edge over DCGO overall, supported by stronger fundamentals and lower modeled downside.
DCGO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
DCGO's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
DCGO PE Valuation
DCGO has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
DCGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect DCGO's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
DCGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.84 | -$1.33 |
| Q2 2026 | -$1.95 | -$1.77 |
| Q1 2026 | -$1.90 | -$1.89 |
| Q4 2025 | -$1.84 | -1122% |
| Q3 2025 | -$0.51 | -289% |
| Q2 2025 | -$0.18 | -167% |
| Q1 2025 | -$0.01 | -105% |
| Q4 2024 | $0.18 | +200% |
DCGO lost $1.84 per share over the past year, a bigger loss than the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over DCGO on earnings quality, reporting a profit while its opponent remains loss making.
DCGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $73.4M | +3.7% |
| Q2 2026 | $73.4M | -8.7% |
| Q1 2026 | $75.6M | -21% |
| Q4 2025 | $74.9M | -38% |
| Q3 2025 | $70.8M | -49% |
| Q2 2025 | $80.4M | -51% |
| Q1 2025 | $96M | -50% |
| Q4 2024 | $120.8M | -39% |
DCGO's revenue has slid since its 2023 peak: $73M last quarter, up 3.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | +36 points |
| Q2 2026 | -24% | -2.7 points |
| Q1 2026 | -25% | -10 points |
| Q4 2025 | -140% | -133 points |
| Q3 2025 | -59% | -67 points |
| Q2 2025 | -22% | -28 points |
| Q1 2025 | -15% | -23 points |
| Q4 2024 | -6.2% | -12 points |
DCGO's operating margin was −24% last quarter, up 36 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over DCGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over DCGO on profitability, with a higher operating margin.
DCGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.7M | -578% |
| Q2 2026 | -$9.6M | -129% |
| Q1 2026 | -$5.1M | -162% |
| Q4 2025 | -$12M | -200% |
| Q3 2025 | $782.6K | -97% |
| Q2 2025 | $32.9M | +2.1% |
| Q1 2025 | $8.2M | +$19.8M |
| Q4 2024 | $12M | +$21.1M |
DCGO's free cash flow was −$30M over the past year, against $54M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over DCGO on cash generation, producing positive trailing cash flow while its opponent burns cash.
DCGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +137K shares |
| 1 year | +1.2% | +1.1M shares |
| 3 years | -5.8% | -6.1M shares |
| 5 years | -1.1% | -1.1M shares |
DCGO has 99M diluted shares, up 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $5.1M |
| Q1 2025 | $5.8M |
| Q4 2024 | $2.7M |
DCGO hasn't bought back shares in the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over DCGO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
DCGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -3.5x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
| Q3 2024 | -1.6x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -0.9x | Net Cash |
| Q4 2023 | -2.2x | Net Cash |
| Q3 2023 | -2.7x | Net Cash |
| Q2 2023 | -8.4x | Net Cash |
DCGO has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
DCGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 4.2 | Oversold |
DCGO's weekly RSI is 28 (oversold) and its Stochastic is 4 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
DCGO PE vs Healthcare Sector
| Metric | DCGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
DCGO has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
DCGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.29 | 21% below |
| 20 week MA | $0.43 | 47% below |
| 50 week MA | $0.60 | 62% below |
| 100 week MA | $1.44 | 84% below |
| 200 week MA | $3.57 | 94% below |
DCGO is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over DCGO on trend strength, trading above more of its moving averages.
DCGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.3 | $10.4 | +0.8% |
| 2021 | $10.4 | $8.71 | -16% |
| 2022 | $8.71 | $6.91 | -21% |
| 2023 | $6.91 | $5.59 | -19% |
| 2024 | $5.59 | $4.38 | -22% |
| 2025 | $4.38 | $0.93 | -79% |
| 2026 YTD | $0.93 | $0.23 | -75% |
DCGO has finished five years in a row lower, and it's down 75% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over DCGO on returns for 2026, with the stronger performance.